Zynerba Press Releases

17 Oct 16 Zynerba Provides Clinical Update for Lead Development Candidates – ZYN001 and ZYN002

13 Sep 16 Zynerba Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer

6 Sep 16 Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences

6 Sep 16 Zynerba Pharmaceuticals Launches Phase 2 Clinical Trial of ZYN002 CBD Gel for Treatment of Osteoarthritis

11 Aug 16 Zynerba Pharmaceuticals Reports Second Quarter 2016 Financial Results and Organizational Changes

3 Aug 16 Zynerba Pharmaceuticals to Present at Canaccord Genuity’s 36th Annual Growth Conference

1 Aug 16 Zynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 CBD Gel in Adult Epilepsy Patients with Refractory Focal Seizures

6 Jul 16 Zynerba Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

27 Jun 16 Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures

1 Jun 16 Zynerba Pharmaceuticals to Participate in Upcoming Investor Meetings and Conferences